← All trials
NCT05481177
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2022
- Primary completion
- Sep 1, 2024
- Completion date
- Sep 1, 2024
- First posted
- Aug 1, 2022
- Last posted
- Nov 23, 2022
- Enrollment
- 250
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Uniformed Services University of the Health SciencesLead sponsor
- Uniformed Services University of the Health SciencesOverall official - principal investigator
- Uniformed Services University of the Health SciencesReponsible party - principal investigator
- Uniformed Services University of the Health SciencesStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.